“Adenovirus vaccine”的意思、由来-开放百科全书

It was used by the United States military from 1971 to 1999, but was discontinued when the only manufacturer stopped production.^[2]^[3] This vaccine elicited immunity to serotypes 4 and 7.^[4] On March 16, 2011, the U.S. Food and Drug Administration approved an adenovirus vaccine manufactured by Teva Pharmaceuticals under contract to the U.S. Army.^[5] This vaccine is essentially the same as the one used from 1971 to 1999. On October 24, 2011 the military services began administering the new adenovirus vaccine to recruits during basic training.

It should not be confused with the strategy of using adenovirus as a carrier to develop vaccines for other pathogens, or as a general gene carrier.^[6]^[7]^[8]

References

1. ^{{cite journal |vauthors =Tucker SN, Tingley DW, Scallan CD |title=Oral adenoviral-based vaccines: historical perspective and future opportunity |journal=Expert Rev Vaccines |volume=7 |issue=1 |pages=25–31 |date=February 2008|pmid=18251691 |doi=10.1586/14760584.7.1.25 |url=http://www.future-drugs.com/doi/abs/10.1586/14760584.7.1.25?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov}}
2. ^{{cite journal |vauthors =Russell KL, Hawksworth AW, Ryan MA |title=Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004 |journal=Vaccine |volume=24 |issue=15 |pages=2835–42 |date=April 2006|pmid=16480793 |pmc=1955759 |doi=10.1016/j.vaccine.2005.12.062 |url=http://linkinghub.elsevier.com/retrieve/pii/S0264-410X(06)00016-8|display-authors=etal}}
3. ^{{cite web |url=http://www.navy.mil/search/display.asp?story_id=26369 |title=Vaccine Trials For "Boot Camp Crud" May Help 20 Percent of Recruits |format= |work= |accessdate=2009-01-15| archiveurl= https://web.archive.org/web/20090212011026/http://www.navy.mil/search/display.asp?story_id=26369| archivedate= 12 February 2009 | deadurl= no}}
4. ^{{cite journal |title=Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000 |journal=MMWR Morb. Mortal. Wkly. Rep. |volume=50 |issue=26 |pages=553–5 |date=July 2001|pmid=11456329 |doi= |url= |author1= Centers for Disease Control and Prevention (CDC)}}
5. ^Malarkey MA, Baylor NW. FDA approval letter dated March 16, 2011.
6. ^{{cite journal |vauthors =Croyle MA, Patel A, Tran KN |title=Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice |journal=PLoS ONE |volume=3 |issue=10 |pages=e3548 |year=2008 |pmid=18958172 |pmc=2569416 |doi=10.1371/journal.pone.0003548 |url=http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003548 |editor1-last=Doolan |editor1-first=Denise L.|display-authors=etal}}
7. ^{{cite journal |vauthors =Hartman ZC, Appledorn DM, Amalfitano A |title=Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications |journal=Virus Res. |volume=132 |issue=1–2 |pages=1–14 |date=March 2008|pmid=18036698 |doi=10.1016/j.virusres.2007.10.005 |url=http://linkinghub.elsevier.com/retrieve/pii/S0168-1702(07)00366-8|pmc=4039020 }}
8. ^{{cite journal |vauthors =Tatsis N, Ertl HC |title=Adenoviruses as vaccine vectors |journal=Mol. Ther. |volume=10 |issue=4 |pages=616–29 |date=October 2004|pmid=15451446 |doi=10.1016/j.ymthe.2004.07.013}}